Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

NCT02336165 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

159

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Durvalumab
RADIATION: Standard radiotherapy
BIOLOGICAL: Bevacizumab

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]
[object Object]